Studies have shown that G6PD mutations in patients with AML may lead to redox imbalance, which, in turn, affects tumor cell growth and drug resistance, especially in FLT3 inhibitor therapy, where G6PD-driven redox metabolism promotes the development of drug resistance [40,46]. The gene discussed is G6PD; the disease is acute myeloid leukemia.